Summary
31 adult patients (study A) with acute myelocytic leukaemia were treated for remission induction with cytosine arabinoside (ARA-C, 100 mg/ m2/day) by a 7 (5) day continuous infusion. 3 (2) doses of daunorubicin (DNR, 45 mg/m2 i.v.) were added at daily intervals. For maintenance 5 day ARA-C was given monthly in sequential combination with DNR, thioguanine (TG), or ifosfamide (IFOS). 16 (52%) patients achieved complete remission (C.R.) after 1.8 (1–23) courses and 6.7 (3–10) weeks from treatment start. The median survival for responders and non-responders was 11.5 months, early death rate within 6 weeks was 3 (10%). Median remission duration was 13.5 months. Among 11 patients surviving for 7–22 months 7 patients are in first remission for 5.5–20.5 months.
DNR, IFOS and TG were not given before the 3rd day of ARA-C infusion. In a previous group of 34 leukaemic patients and in 44 therapy courses DNA histograms of bone marrow cells using pulse cytophotometry showed marked accumulation in S-phase for 75% of courses. Also (G2 + M)-cells in the DNA distribution and thymidine pulse labelling indices were markedly increased in most cases, whereas thymidine uptake by scintillation counter was diminished and mitotic indices had not changed significantly.
In now 15 patients (study B) the induction regimen was intensified by adding vincristine (VCR, 2 mg i.v.) and 3 doses of IFOS (600 mg/m2 i.V.). Preliminary results are 50% C.R. after 1,7 (1–2) courses and 6.8 (5–10) weeks from initiation of therapy. 2 patients died in the first 6 weeks.
Modification and intensification of established drug combinations for AML on the basis described appear reasonable and possible.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Bekesi, J.G., Holland, J.F., Roboz, J.P.: Specific immunotherapy with neuraminidasemodified leukemic cells. Med. Clin. North Amer.61, 083 (1977)
Bodey, G.P., Coltman, C.A., Hewlett, J.S., Freireich, E.J. (SWOG): Progress in the treatment of adults with acute leukemia. Arch, intern. Med.136, 383 (1976)
Büchner, Th., Barlogie, B., Asseburg, U., Hiddemann, W., Kamanabroo, D., Göhde, W.: Accumulation of S-phase cells in the bone marrow of patients with acute leukemia by cytosine arabinoside. Blut28, 299 (1974)
Büchner, Th., Göhde, W., Schumann, J., Barlogie, B.: In vivo kinetic response of human leukemic cells to antileukemic drugs as seen in the DNA-histogram. In: Proc. 16th Internat. Congr. Hematol., Kyoto; pp. 265 269, Amsterdam: Excerpta Medica 1976
Büchner, Th., Barlogie, B., Metz, K.G., Hortebusch, H.H., Ortheil, N.: Cell kinetic response to cytosine arabinoside in the L 5222 rat leukemia. Leukemia Research1, 241 (1977)
Bull, J.M., Duttera, M.J., Stashick, E.D., Northup, J., Henderson, E., Carbone, P.P.: Serial in vitro marrow culture in acute myelocytic leukemia. Blood42, 679 (1973)
Burge, P.S., Richards, J.D.M., Thrompson, D.S., Prankerd, T.A.J., Sare, M., Wright, P.: Quality and quantity of survival in acute leukemia. LancetII, 621 (1975)
Carey, R.W., Ribas-Mundo, M., Ellison, R.R., Glidewell, O., Lee, S.T., Cuttner, J., Levy, R.N., Silver, R., Blom, J., Haurani, F., Spurr, C.L., Harley, J.B., Kyle, R., Moon, J.H., Eagan, R.T., Holland, J.H.: Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia. Cancer36, 1560 (1975)
Clarkson, B.D., Dowling, M.D., Gee, T.S., Cunningham, I.B., Burchenal, J.H.: Treatment of acute leukemia in adults. Cancer36, 775 (1975)
Fülle, H.H.: Induktions- und Erhaltungstherapie der akuten myeloischen Leukemie des Erwachsenen durch sequentielle Anwendung cytostatischer Chemotherapiekombinationen. Med. Klin.72, 642 (1977)
Gale, R.P., Cline, M.J.: High remission induction rate in acute myeloid leukemia. LancetII, 497 (1977)
Gerecke, D., Hirschmann, W. D., Voigtmann, R., Hellriegel, K. P.: Rezidivprophylaxe bei akuter, nicht-lymphozytärer Leukämie im Erwachsenenalter mit 6-Mercaptopurin und Methotrexat sowie COAP-Reinduktion. Abstr. Jahrestg. Österr. u. Dtsch. Ges. Hämatol., Linz 1977
Greenberg, P., Box, I., Mara, B., Schrier, S.: Alterations of granulopoiesis following chemotherapy. Blood44, 375 (1974)
Gutterman, J.U., Rodriguez, V., Mavligit, G., Burgess, M.A., Gehan, E., Hersh, E.M., McCredie, K.B., Reed, R., Smith, T., Bodey, G.P., Freireich, E.J.: Chemoimmunotherapy of adult acute leukemia. LancetII, 1405 (1974)
Harriss, E.B., Hoelzer, D.: Proliferative state of normal in vitro colony forming cells during development of the L 5222 rat leukemia and their reaction to chemotherapy. Blood51, 221 (1978)
Lampkin, B.C., McWilliams, N.B., Mauer, A.M., Flessa, H.C., Hake, D.A., Fisher, V.: Manipulation of the mitotic cycle in the treatment of acute myelogenous leukemia. Br. J. Haematol.32, 29 (1976)
Manasler, J., Cowan, D.H., Curtis, J.E., Hasselbach, R., Bergsagel, D.E.: Remission maintenance of acute nonlymphoblastic leukemia with BCNU and cyclophosphamide. Cancer Chemother. Rep.59, 537 (1975)
Powles, R.L., Russell, J., Lister, T.A., Oliver, T., Whitehouse, J.M.A., Malpas, J., Chapuis, B., Crowther, D., Alexander, P.: Immunotherapy for acute myelogenous leukemia: A controlled clinical study 21/2 years after entry of the last patient. Br. J. Cancer35, 265 (1977)
Pralle, H., Löffler, H.: Erfahrungen mit der Kombinationschemotherapie (COAP- und TRAP-Schemata) bei unreifzelligen granulocytären Leukämien (Peroxydase-Typ) des Erwachsenen. Med. Welt26, 1783 (1975)
Sotto, J.J., Hollard, D., Schaerer, R., Bensa, J.C., Seigneurin, D.: Androgènes et rémissions prolongées dans les leucémies aiguës non lymphoblastiques. Nouv. Rev. Hémat.15, 57 (1975)
Vogler, W.R., Cooper, L.E., Groth, D.P.: Correlation of cytosine arabinoside-induced increment in growth fraction ofleukemic blast cells with clinical response. Cancer33, 603 (1974)
Weil, M., Jacquillat, C.I., Gemmon-Auclerc, M.F., Chastang, C.L., Izrael, V., Boiron, M., Bernard, J.: Acute granulocytic leukemia: treatment of the disease. Arch. intern. Med.136, 1389 (1976)
Wiernick, P.H.: Advances in the management of acute nonlymphocytic leukemia. Arch. intern. Med.136, 1399 (1976)
Yates, J.W., Wallace, H.J. Jr., Ellison, R.R., Holland, J.F.: Cytosine arabinoside and daunorubicin therapy in acute nonlymphocytic leukemia. Cancer Chemother. Rep.57, 81 (1973)
Author information
Authors and Affiliations
Additional information
Herrn Prof Dr. W. H. Hauss zum 70. Geburtstag gewidmet.
Rights and permissions
About this article
Cite this article
Büchner, T., Kamanabroo, D., Urbanitz, D. et al. Induktionsbehandlung der akuten myeloischen Leukämie mit Cytosin-Arabinosid — Daunorubicin, zusätzlicher Effekt von Ifosfamid und Vincristin. Blut 36, 371–376 (1978). https://doi.org/10.1007/BF01000596
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01000596